Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-30T04:26:36.531Z Has data issue: false hasContentIssue false
  • English
  • Français

Pplication of the valproate in Schizophrenia, with Treatment Resistant Verbal Hallucinosis

Published online by Cambridge University Press:  16 April 2020

N. Aliyev  and
Z. Aliyev
N. Aliyev
Affiliation:
Central Mental Clinic for Outpatients of Baku City, Azerbaijan
Z. Aliyev
Affiliation:
Psychiatric Department of Azerbaijan State Medical University, Baku, Azerbaijan

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background

The goal of this study vas to examine the efficacy of valpoate (depakine-chrono) with combination by haloperidol decanoat in schizophrenia patients with treatment resistant verbal hallucinosis.

Methods

46 outpatients (men) diagnosed according to ICD-10. Patients treated haloperidol decoanat (in ampoules) 100 mg intramuscularly over 7 days plus 1500 mg depakine-chrono (in caps.) in day, per os. Treatment duration was 7 to 28 days. The expressiveness of psychopathology was estimated 7 balls system by the positive scale score of PANSS. The significance of differences between baseline and at the termination was assessed by the Wilcoxon Rank Sum Test.

Results

All surveyed patients apparently efficiency of treatment of schizophrenia with verbal hallucinosis after treatment was higher statistically significance.

Conclusion

Haloperidol decanoat with the combination by depakin chrono represents a usefully method for the treatment of patients with treatment resistant verbal hallucinosis.

Type
P03-170
Information
European Psychiatry , Volume 26 , Issue S2: Abstracts of the 19th European Congress of Psychiatry , March 2011 , pp. 1339
Copyright
Copyright © European Psychiatric Association 2011
Submit a response

Comments

No Comments have been published for this article.